ARIA
Library/immune/Thymosin Alpha-1

Thymosin Alpha-1

Not FDA Approved✓ WADA Permitted

Tα1 / Zadaxin

immune◈Clinical EvidenceThymic peptide

28-AA peptide from thymosin fraction 5. Immune modulator. Approved in 30+ countries (not FDA-approved). Used for hepatitis B/C, immune support, cancer adjunct. Restores immune balance in liver failure.

Confidence
72%
Half-Life ~2 hours
Cost ~$800/mo
Quick Reference
Routesubcutaneous
MechanismEnhances T-cell maturation and function. Upregulates MHC class I. Stimulates IFN...
SequenceSDAAVDTSSEITTKDLKEKKEVVEEAENGRDAPANGNANEENGEQEADNEVSTLG
Mol. Weight3108.5 Da
Reviewed2026-07-08

Mechanism of Action

Enhances T-cell maturation and function. Upregulates MHC class I. Stimulates IFN-γ, IL-2. Enhances NK cell activity. Restores Th1/Th2 balance. TLR-2 and TLR-9 agonist.

Dosing Protocol

1.6mg SC 2x/week. Cycle 6-12 months for chronic conditions.

Key Studies

2026

Tα1 in HBV-related ACLF

PMID 41887933cohort
2025

Aging and Thymosin Alpha-1

PMID 41373628review

Adverse Effects

Generally well toleratedInjection site reactionsRare hypersensitivity

Contraindications

  • Organ transplant recipients (relative)
  • Pregnancy (insufficient data)

Storage

Refrigerate at 2-8°C. Protect from light. Stable for 2 years when refrigerated.

Clinical Applications

  • ["immune_support"
  • "immune_modulation"
  • "anti_aging"]